C57BL/6JCya-Mycem1/Cya
Common Name:
Myc-KO
Product ID:
S-KO-03294
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Myc-KO
Strain ID
KOCMP-17869-Myc-B6J-VA
Gene Name
Product ID
S-KO-03294
Gene Alias
Myc2; Niard; Nird; bHLHe39
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
15
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Mycem1/Cya mice (Catalog S-KO-03294) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000022971
NCBI RefSeq
NM_010849.4
Target Region
Exon 2~3
Size of Effective Region
~4.3 kb
Detailed Document
Overview of Gene Research
MYC, a proto-oncogene, consists of 3 paralogs: C-MYC, N-MYC, and L-MYC. It functions as a universal amplifier of transcription, regulating diverse cellular processes such as cell cycle, proliferation, metabolism, differentiation, and apoptosis [2,3,4,5]. MYC is frequently deregulated in human cancers, being dysregulated in approximately 70% of cases, and is involved in tumor initiation and maintenance, making it an appealing therapeutic target [1].
In vivo studies have shown that MYC inhibition leads to anti-proliferative effects and tumor regression while causing reversible changes in healthy tissue [1]. Some compounds that directly or indirectly inhibit MYC have demonstrated anticancer activity in preclinical tumor models [2]. Strategies for targeting MYC include inhibiting its binding to MAX, preventing its expression, and blocking genes with synthetic lethality upon MYC overexpression [2].
In conclusion, MYC is a key regulator of multiple cellular functions. The findings from in vivo studies on MYC inhibition highlight its potential as a therapeutic target in cancer treatment. Understanding MYC's role through such model-based research is crucial for developing effective cancer therapies.
References:
1. Llombart, Victor, Mansour, Marc R. 2021. Therapeutic targeting of "undruggable" MYC. In EBioMedicine, 75, 103756. doi:10.1016/j.ebiom.2021.103756. https://pubmed.ncbi.nlm.nih.gov/34942444/
2. Duffy, Michael J, O'Grady, Shane, Tang, Minhong, Crown, John. 2021. MYC as a target for cancer treatment. In Cancer treatment reviews, 94, 102154. doi:10.1016/j.ctrv.2021.102154. https://pubmed.ncbi.nlm.nih.gov/33524794/
3. Das, Subhendu K, Lewis, Brian A, Levens, David. 2022. MYC: a complex problem. In Trends in cell biology, 33, 235-246. doi:10.1016/j.tcb.2022.07.006. https://pubmed.ncbi.nlm.nih.gov/35963793/
4. Baluapuri, Apoorva, Wolf, Elmar, Eilers, Martin. 2020. Target gene-independent functions of MYC oncoproteins. In Nature reviews. Molecular cell biology, 21, 255-267. doi:10.1038/s41580-020-0215-2. https://pubmed.ncbi.nlm.nih.gov/32071436/
5. Jha, Rajiv Kumar, Kouzine, Fedor, Levens, David. 2023. MYC function and regulation in physiological perspective. In Frontiers in cell and developmental biology, 11, 1268275. doi:10.3389/fcell.2023.1268275. https://pubmed.ncbi.nlm.nih.gov/37941901/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen